89bio Inc (ETNB)
8.58
-0.34
(-3.81%)
USD |
NASDAQ |
Apr 24, 16:00
8.57
-0.01
(-0.12%)
After-Hours: 20:00
89bio Cash from Investing (TTM): -123.02M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -123.02M |
| September 30, 2023 | -70.44M |
| June 30, 2023 | -150.82M |
| March 31, 2023 | -56.61M |
| December 31, 2022 | -33.94M |
| September 30, 2022 | -3.796M |
| June 30, 2022 | 55.62M |
| March 31, 2022 | 49.34M |
| December 31, 2021 | 7.159M |
| Date | Value |
|---|---|
| September 30, 2021 | -40.96M |
| June 30, 2021 | -130.31M |
| March 31, 2021 | -122.18M |
| December 31, 2020 | -106.83M |
| September 30, 2020 | -77.92M |
| June 30, 2020 | -5.924M |
| March 31, 2020 | -0.198M |
| December 31, 2019 | -0.139M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-150.82M
Minimum
Jun 2023
55.62M
Maximum
Jun 2022
-47.70M
Average
-40.96M
Median
Sep 2021
Cash from Investing (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | -502.52M |
| Akero Therapeutics Inc | -223.62M |
| Viking Therapeutics Inc | -179.09M |
| Galectin Therapeutics Inc | -- |
| Terns Pharmaceuticals Inc | -37.99M |